Abstract
The redistribution of healthcare resources for coronavirus 2019 (COVID-19) pandemic has resulted in unintentional neglect of essential non-COVID-19 care (1). In low- and lower-middle income countries (LMIC), the already overstretched healthcare systems have crumbled under the COVID-19 pressure (2). Additionally, hardline lockdown restrictions, and fear of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in healthcare settings have forced patients with non-COVID-19 illnesses to stay home and suffer until their illness deteriorates substantially, and sometimes irreversibly. The impact of COVID-19 on the pediatric population has so far been mild, except in children with comorbidities (3). However, children who develop new time-sensitive non-COVID-19 illnesses during the pandemic are at risk of worsening or death due to compromised access to hospital care. In particular, children with new-onset type 1 diabetes (T1D) may progress rapidly to diabetic ketoacidosis (DKA) if treatment with insulin is delayed, and are therefore at risk of increased morbidity and mortality.
Missing during COVID-19 lockdown: children with new-onset type 1 diabetes
